Analysts Offer Insights on Healthcare Companies: Seattle Genetics (NASDAQ: SGEN), Array Biopharma (NASDAQ: ARRY) and BioMarin (NASDAQ: BMRN)

By Carrie Williams

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Seattle Genetics (NASDAQ: SGEN), Array Biopharma (NASDAQ: ARRY) and BioMarin (NASDAQ: BMRN).

Seattle Genetics (NASDAQ: SGEN)

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Seattle Genetics (NASDAQ: SGEN) yesterday and set a price target of $54. The company’s shares opened today at $58.71.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 21.4% and a 51.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Madrigal Pharmaceuticals Inc, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Seattle Genetics is Moderate Buy and the average price target is $64.90, representing a 10.5% upside.

In a report issued on March 7, Oppenheimer also assigned a Hold rating to the stock.
Array Biopharma (NASDAQ: ARRY)

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Array Biopharma (NASDAQ: ARRY) yesterday and set a price target of $19. The company’s shares opened today at $18.03, close to its 52-week high of $18.78.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 26.9% and a 56.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Five Prime Therapeutics.

Array Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $20.

BioMarin (NASDAQ: BMRN)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on BioMarin (NASDAQ: BMRN), with a price target of $150. The company’s shares opened today at $85.60.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.2% and a 57.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Alpine Immune Sciences Inc, and Rhythm Pharmaceuticals Inc.

Currently, the analyst consensus on BioMarin is Strong Buy and the average price target is $120.45, representing a 40.7% upside.

In a report issued on March 2, Credit Suisse also maintained a Buy rating on the stock with a $116 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.